TrialJournal of clinical pharmacology2026

First-In-Human Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of Tilpisertib Fosmecarbil (GS-5290), an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor in Healthy Participants.

Priyanka A Madia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.